What is the normal QRS duration on a baseline ECG before initiating lithium therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Normal QRS Duration Before Lithium Therapy

The normal QRS duration should be less than 120 ms in adults before initiating lithium therapy 1.

Standard QRS Duration Parameters

Based on established cardiology guidelines, normal QRS duration varies by age 1:

  • Adults: <120 ms (normal); 110-119 ms (borderline/incomplete conduction delay)
  • Children 8-16 years: <100 ms (normal); 90-100 ms (borderline)
  • Children <8 years: <90 ms (normal); 80-90 ms (borderline)

Any QRS duration ≥120 ms in adults indicates an intraventricular conduction disturbance (complete bundle branch block or nonspecific conduction delay) 1.

Why This Matters for Lithium Therapy

Lithium can cause ECG changes that affect cardiac conduction. Establishing a baseline normal QRS duration is critical because lithium may widen the QRS complex during treatment 2, 3. In one study, 61.5% of patients showed increased QRS duration after therapeutic lithium treatment 2. Case reports document lithium-induced wide QRS complexes that can mimic acute coronary syndrome or unmask Brugada syndrome 3.

Key Baseline ECG Considerations

Before starting lithium, document:

  • QRS duration (should be <120 ms)
  • QTc interval (lithium can prolong this 2, 4)
  • PR interval (may increase slightly with lithium 5)
  • T-wave morphology (flattening/inversion is the most common lithium-induced change 5)

Clinical Pitfalls to Avoid

Do not start lithium if the baseline QRS is ≥120 ms without cardiology consultation, as pre-existing conduction disease increases risk of symptomatic bradycardia and sinus node dysfunction 6. The FDA label specifically warns about "sinus node dysfunction with severe bradycardia" and cardiac arrhythmias as adverse effects 6.

Patients with elevated systolic blood pressure (>134 mmHg) are at higher risk for lithium-induced ventricular conduction delays 2, warranting closer ECG monitoring.

While routine ECG monitoring during stable lithium therapy may not be necessary at therapeutic levels (0.6-1.2 mEq/L) 5, 4, obtaining a baseline ECG with normal QRS duration (<120 ms) is essential for comparison if cardiac symptoms develop during treatment.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.